UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 23, 2013
AFFYMAX, INC.
(Exact name of registrant as specified in charter)
Delaware |
| 001-33213 |
| 77-0579396 |
(State or other jurisdiction of |
| (Commission File Number) |
| (I.R.S. Employer Identification No.) |
incorporation) |
|
|
|
|
4001 Miranda Avenue
Palo Alto, California 94304
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (650) 812 -8700
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On February 23, 2013, Affymax, Inc. (the “Company”) and Takeda Pharmaceutical Company Limited (“Takeda”) announced a nationwide voluntary recall of OMONTYS® (peginesatide) Injection as a result of new postmarketing reports regarding serious hypersensitivity reactions, including anaphylaxis which can be life-threatening or fatal.
A press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statement and Exhibits.
(d) Exhibits:
Exhibit No. |
| Description |
99.1 |
| Affymax and Takeda Announce a Nationwide Voluntary Recall of All Lots of OMONTYS ® (peginesatide) Injection |
